SCHEDULE: Vanguard Group Amends IDEXX Ownership Disclosure

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in IDEXX Laboratories Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 15 to Schedule 13G regarding its beneficial ownership of Common Stock in IDEXX Laboratories Inc.
• The filing indicates that The Vanguard Group, Inc. now holds 0% beneficial ownership in IDEXX Laboratories Inc.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. It reflects a change in reporting structure for The Vanguard Group, not a change in the investment thesis or performance of IDEXX Laboratories Inc.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that such administrative filings by large institutional investors like The Vanguard Group are common, especially after internal restructurings or changes in reporting methodologies. This particular filing reflects a disaggregation of reporting rather than a complete divestment of the underlying shares by the broader Vanguard organization.

Stakeholder Impact

• Shareholders of IDEXX Laboratories Inc. should note that this filing represents a change in how Vanguard's beneficial ownership is reported, not necessarily a complete divestment of all IDEXX shares by Vanguard's various funds and entities.

Key Dates

Recommendation

This filing is an administrative update regarding The Vanguard Group's internal reporting structure for beneficial ownership and does not reflect a change in the fundamental investment outlook for IDEXX Laboratories Inc. or a divestment of all IDEXX shares by Vanguard's broader investment vehicles. Therefore, a 'hold' recommendation is appropriate as the filing itself provides no new information to alter an existing investment thesis.

Keywords

IDEXX Laboratories, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Ownership Disclosure